Literature DB >> 4608231

Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10.

M Fujino, T Fukuda, S Shinagawa, S Kobayashi, I Yamazaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4608231     DOI： 10.1016/0006-291x(74)90219-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


× No keyword cloud information.
  12 in total

Review 1.  Clinical pharmacokinetics of depot leuprorelin.

Authors:  Piero Periti; Teresita Mazzei; Enrico Mini
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.

Authors:  Neal Shore; Ivan Mincik; Mark DeGuenther; Vladimir Student; Mindaugas Jievaltas; Jitka Patockova; Kelle Simpson; Chu-Hsuan Hu; Shih-Tsung Huang; Yuhua Li; Yisheng Lee; Ben Chien; John Mao
Journal:  World J Urol       Date:  2019-04-03       Impact factor: 4.226

Review 3.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

4.  Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans.

Authors:  A Adjei; D Sundberg; J Miller; A Chun
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

5.  A convenient approach to synthesizing peptide C-terminal N-alkyl amides.

Authors:  Wei-Jie Fang; Tatyana Yakovleva; Jane V Aldrich
Journal:  Biopolymers       Date:  2011-02-09       Impact factor: 2.505

Review 6.  Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic.

Authors:  Samer R Abulateefeh
Journal:  Drug Deliv Transl Res       Date:  2022-08-17       Impact factor: 5.671

7.  Does a gonadotropin-releasing hormone analogue prevent cisplatin-induced spermatogenic impairment? An experimental study in the mouse.

Authors:  M Nonomura; K Okada; S Hida; O Yoshida
Journal:  Urol Res       Date:  1991

8.  Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis.

Authors:  Irene Guzmán-Soto; Eva Salinas; Irma Hernández-Jasso; J Luis Quintanar
Journal:  Neurochem Res       Date:  2012-07-26       Impact factor: 3.996

9.  Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.

Authors:  E David Crawford; Jason M Phillips
Journal:  Cancer Manag Res       Date:  2011-07-20       Impact factor: 3.989

Review 10.  Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.

Authors:  Rajni Sethi; Nicholas Sanfilippo
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.